TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases.
TEM-28 (pI 6.1), expressed by an Escherichia coli clinical isolate, is a novel beta-lactamase which hydrolyzed ceftazidime, cefotaxime, and aztreonam with rates of 25, 1.1, and 5.6, respectively, relative to that for benzylpenicillin (100). The nucleotide sequence of blaTEM-28 differed from that of blaTEM-1 by two base changes, resulting in amino acid substitutions of Arg-164 to His and Glu-240 to Lys.
Bradford
P A
PA
Wyeth-Ayerst Research, Lederle Laboratories, Pearl River, New York 10965, USA. bradforp@war.wyeth.com.com.
Jacobus
N V
NV
Bhachech
N
N
Bush
K
K
D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000201:enzymology* / Q000235:genetics / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000201:enzymology* / Q000382:microbiology*; D007525:Isoelectric Focusing; D010957:Plasmids; D014170:Transformation, Genetic; D001618:beta-Lactamases / Q000235:genetics / Q000302:isolation & purification*
D001618:beta-Lactamases; C034413:beta-lactamase TEM-1